Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2017-12-31, filed 2018-02-14, with 27 holding rows worth $410,635,000.

Accession
0001172661-18-000559
Filed
2018-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2017

A holdings report, 27 entries on the cover page, a total value of $410,635,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $410,635,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SAGE THERAPEUTICS INC78667J108COM250,000$41,178,000thousands by filing date
Foundation Medicine Inc350465100COM520,000$35,464,000thousands by filing date
LOXO ONCOLOGY INC548862101COM360,000$30,305,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM348,000$26,243,000thousands by filing date
BLUEBIRD BIO INC09609G100COM145,000$25,825,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock200,000$25,410,000thousands by filing date
MYOKARDIA INC62857M105COM560,000$23,576,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM1,400,000$22,960,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM515,000$20,265,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK1,135,000$18,841,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM295,000$16,865,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM2,600,000$15,886,000thousands by filing date
SPARK THERAPEUTICS INC84652J103COM302,474$15,553,000thousands by filing date
CODEXIS INC192005106COM1,600,000$13,360,000thousands by filing date
EVOLENT HEALTH INC CL A30050B101Stock1,077,500$13,253,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock400,000$12,500,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM2,730,000$11,384,000thousands by filing date
ILLUMINA INC452327109COM44,000$9,614,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM127,500$8,670,000thousands by filing date
JOUNCE THERAPEUTICS INC481116101COM475,000$6,056,000thousands by filing date
EDITAS MEDICINE INC28106W103COM133,333$4,097,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK177,500$3,747,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM274,074$2,667,000thousands by filing date
Gilead Sciences,Inc.375558103COM30,000$2,149,000thousands by filing date
BEONE MEDICINES LTD SPONSORED ADS07725L102ADR18,000$1,759,000thousands by filing date
OVID THERAPEUTICS INC690469101COMMON STOCK160,000$1,579,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM25,000$1,429,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-18-000559this filing2018-02-14acceptance time not in the bulk data set